Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant for hot flashes in women unsuitable for HRT
NCT05033886Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant 45 mg with Placebo (2 arms). Primary endpoint: Mean change in the frequency of moderate to severe VMS from baseline at 24 weeks. Started Nov 2021; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05033886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033886.